

The Osteoarthritis Initiative

Goals

- To create a research resource to aid in the identification and evaluation of biomarkers as candidates for surrogate endpoints for OA

Mechanism

- Development of prospective, natural history cohort to be followed for 5 years
- Materials to be collected: clinical and imaging data and biospecimens

Government partners:

Nat'l Institute of Arthritis, Musculoskeletal & Skin Diseases

Nat'l Institute on Aging

Nat'l Institute of Dental & Craniofacial Research

Nat'l Center for Complementary & Alternative Medicine

Nat'l Center on Minority Health & Health Disparities

Office of Research on Women's Health, NIH

Private partners:

Pfizer, Inc.

Novartis Pharmaceuticals Corporation

Merck & Company, Inc.

The Data Coordinating Center is

University of California, San Francisco (PI, Michael Nevitt, PhD).

The Clinical Centers are

The Ohio State University, Columbus, OH (PI, Rebecca Jackson, MD);

University of Maryland School of Medicine, Baltimore, MD (PI, Marc Hochberg, MD, MPH);

University of Pittsburgh, Pittsburgh, PA (PI, C. Kent Kwoh, MD)

Memorial Hospital Rhode Island, Pawtucket, RI (PI, Charles Eaton, MD)

Gayle Lester, PhD
NIAMS, NIH, DHHS
June 7, 2004
FAC

Research resources from OAI should

- stimulate basic research on biomarkers
- facilitate drug development through
 - identification of biomarkers of disease onset
 - identification of biomarkers of disease progression
 - elucidation of the basic disease processes and risk factors

Long term results of the OAI may include:

More thorough understanding of OA and its manifestations in at risk populations

Positive and interactive relationships between groups involved

More efficient safety and efficacy assessments in clinical trials

OA PREVENTION & TREATMENT


